
Autolus Therapeutics (AUTL) Stock Forecast & Price Target
Autolus Therapeutics (AUTL) Analyst Ratings
Bulls say
Autolus Therapeutics is a promising company that is developing a next-generation T-cell therapy for cancer. Despite facing potential competition, their pipeline of treatments and positive feedback from key opinion leaders positions them well for success in the market. Additionally, their expansion efforts and potential for market share in both cancer and other diseases, along with low risk of side effects and positive results in early trials, make them a strong investment option.
Bears say
Autolus Therapeutics is facing operational challenges such as high COGS, lower than expected operating expenses, and production capability constraints, and strategic challenges such as decreased market potential due to high costs and limited production capability. Additionally, data from its clinical trials in progressive MS and SLE/LN have not been released, making it difficult to determine its potential success in these markets and adding to the overall uncertainty of the company's outlook.
This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Autolus Therapeutics (AUTL) Analyst Forecast & Price Prediction
Start investing in Autolus Therapeutics (AUTL)
Order type
Buy in
Order amount
Est. shares
0 shares